Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2003
03/06/2003US20030044915 Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent
03/06/2003US20030044893 Nectin polypeptides, polynucleotides, methods of making and use thereof
03/06/2003US20030044888 Polypeptide for use in the treatment of addison's disease
03/06/2003US20030044863 Diagnosing cancer in humans; obtain tissue sample, detect invasive complexes associated tissus, evaluate for cancer
03/06/2003US20030044813 Diagnosing cancer in humans; obtain tissue, incubate with marker agent, detect signal, evaluate for cancer
03/06/2003US20030044809 Detection of preferential transcription factor; obtain library, screen with probe, detect hybridization, recover clone, monitor transcriptional activity of protein codes in cloned nucleotide sequences
03/06/2003US20030044783 Human genes and gene expression products
03/06/2003US20030044773 Genetically engineering viral polypeptide; obtain nucleotide sequences coding polypeptide, insert codon, clone into vector, transform cell, detect expression of genetically engineered polypeptide
03/06/2003US20030044514 Using supercritical fluids to infuse therapeutic on a medical device
03/06/2003US20030044424 Novel immune enhancing compositions
03/06/2003US20030044419 Use of reagents derived from nucleic acid and amino acid sequences of Int6 gene in diagnostic methods, immunotherapy, gene therapy and as vaccines
03/06/2003US20030044409 Complexing to epitope; cancer immunotherapy
03/06/2003US20030044401 Anticancer agents; prevent drug resistance
03/06/2003US20030044387 Liver cancer therapy
03/06/2003US20030044386 Genetic engineering; nucleic acid coding cytokines
03/06/2003US20030044385 Antitumor, anticancer agents
03/06/2003US20030044352 Autoimmune disease, anticarcinogenic agents
03/06/2003US20030044114 Source wavelength shifting apparatus and method for delivery of one or more selected emission wavelengths
03/06/2003US20030041602 Process for production of nanoparticles and microparticles by spray freezing into liquid
03/06/2003DE10129369C1 Wasserlösliches, einen Aminozucker aufweisendes Antibiotikum in Form eines Pol ysaccharid-Konjugats Water-soluble, an amino sugar exhibiting antibiotic in the form of a pole ysaccharid conjugate
03/06/2003CA2496180A1 Nucleic acid and polypeptide linked to breast cancer and uses therefor
03/06/2003CA2459183A1 Amplified oncogenes and their involvement in cancer
03/06/2003CA2458924A1 Casein derived peptides and uses thereof in therapy
03/06/2003CA2458627A1 Human cdr-grafted antibody and antibody fragment thereof
03/06/2003CA2458574A1 Reagents and methods for smooth muscle therapies
03/06/2003CA2458565A1 New angiogenesis inhibitors based on soluble cd44 receptor hyaluronic acid binding domain
03/06/2003CA2458506A1 Wild-type ras as a cancer therapeutic agent
03/06/2003CA2458476A1 Photoreactive compounds and compositions
03/06/2003CA2458445A1 Extracellular messengers
03/06/2003CA2458443A1 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003CA2458381A1 Transmembrane protein differentially expressed in cancer
03/06/2003CA2458226A1 Improved nitroreductase enzymes
03/06/2003CA2458182A1 Method for assessing cancerous state of mammal-derived specimen
03/06/2003CA2458131A1 Jnk activation inhibitor
03/06/2003CA2458011A1 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
03/06/2003CA2457903A1 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
03/06/2003CA2457846A1 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
03/06/2003CA2457838A1 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents
03/06/2003CA2457676A1 Chemotherapeutic agents
03/06/2003CA2457589A1 Porphyrins with enhanced multi-photon absorption cross-sections for photodynamic therapy
03/06/2003CA2457532A1 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/06/2003CA2457341A1 A new extended release oral dosage form
03/06/2003CA2457339A1 A new extended release oral dosage form
03/06/2003CA2457118A1 Targeted bisplatinum polyamines as pro-drugs: selective release of platinum
03/06/2003CA2456348A1 Platinum complexes and their uses in therapy
03/06/2003CA2456280A1 Cyclopropyl and cyclobutyl epothilone analogs
03/06/2003CA2456269A1 Methods of inhibiting formation of vascular channels and profileration using pyridinone derivatives
03/06/2003CA2455311A1 Rapamycin dialdehydes
03/06/2003CA2455308A1 Rapamycin 29-enols
03/06/2003CA2430267A1 Hydrazinopeptoids and their uses for treating cancers
03/06/2003CA2421499A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the same and pharmaceutical agent containing the same as active ingredient
03/05/2003WO2002020566A2 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3?
03/05/2003EP1288297A1 Regulation of mt1-mmp activity
03/05/2003EP1288292A1 Long peptides of 22-40 amino acid residues that induce and/or enhance antigen specific immune responses.
03/05/2003EP1288291A1 Method of amplifying natural killer t cells
03/05/2003EP1288227A1 Coactivator of nuclear receptors
03/05/2003EP1288224A1 Therapeutic peptide derivatives
03/05/2003EP1288223A1 Therapeutic peptide derivatives
03/05/2003EP1288222A1 Peptidic compounds selectively binding to P-selectin
03/05/2003EP1288216A1 Tricyclic quinazolinediones
03/05/2003EP1288206A1 Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
03/05/2003EP1288205A1 Novel phenylalanine derivatives
03/05/2003EP1287854A1 Anti-cancer combinations of DMXAA and paclitaxel or docetaxel
03/05/2003EP1287831A1 Antigen mimotopes and vaccine against cancerous diseases
03/05/2003EP1287830A1 Use of methioninase as an antitumor agent in anti-methionine chemotherapy
03/05/2003EP1287825A1 Blends comprising a substituted fatty acid or a derivative thereof
03/05/2003EP1287362A2 Compositions and methods for modulating tumor specific expression
03/05/2003EP1287147A2 Immunotoxin fusion proteins and means for expression thereof
03/05/2003EP1287141A2 Extracellular messengers
03/05/2003EP1287137A2 REGULATION OF HUMAN $g(a)1A?ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR
03/05/2003EP1287130A2 Mammalian cytokine receptor subunit proteins, related reagents and methods
03/05/2003EP1287121A2 Extracellular domain of ryk protein for regulating angiogenesis
03/05/2003EP1287120A2 Human circulating dendritic cell compositions and methods
03/05/2003EP1287115A2 Retinal pigment epithelial cell lines with extended life-span and their applications
03/05/2003EP1287035A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
03/05/2003EP1287034A2 Derivatives of breast cancer antigen her-2 for therapeutical use
03/05/2003EP1287031A2 Polynucleotides encoding for polymorphic isoforms of the pthrp protein, the encoded proteins and their therapeutic applications thereof
03/05/2003EP1287029A2 Compositions and methods for the therapy and diagnosis of colon cancer
03/05/2003EP1287028A2 Compositions and methods for the therapy and diagnosis of colon cancer
03/05/2003EP1287020A2 Cancer diagnosis and assays for screening anti-cancer agents
03/05/2003EP1287017A1 2-substituted pregna-1,3,5(10)-triene and chola-1,3,5(10)-triene derivatives and their biological activity
03/05/2003EP1287015A1 Extracellular matrix polynucleotides, polypeptides, and antibodies
03/05/2003EP1287006A1 Antitumoral compounds
03/05/2003EP1287004A1 Synthetic process for the manufacture of an ecteinascidin compound
03/05/2003EP1287001A1 Thiophene derivatives useful as anticancer agents
03/05/2003EP1286994A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
03/05/2003EP1286990A1 Stolonoxides
03/05/2003EP1286989A2 Prodrug of an ice inhibitor
03/05/2003EP1286987A1 Heterocyclic hydrazones for use as anti-cancer agents
03/05/2003EP1286986A1 Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
03/05/2003EP1286972A1 Pyrimidine compounds
03/05/2003EP1286966A1 4-aminopiperidine derivatives and their use as medicine
03/05/2003EP1286964A1 Heterocyclic inhibitors of glycogen synthase kinase gsk-3
03/05/2003EP1286962A1 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
03/05/2003EP1286705A2 Bioconjugates of nanoparticles as radiopharmaceuticals
03/05/2003EP1286703A2 Methods and compounds for controlled release of recombinant parvovirus vectors
03/05/2003EP1286698A1 Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activity
03/05/2003EP1286693A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
03/05/2003EP1286692A1 Intrathecal administration of rituximab for treatment of central nervous system lymphomas
03/05/2003EP1286691A2 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
1 ... 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 ... 2211